Rabeprazole sodium
Rabeprazole sodium structure
|
Common Name | Rabeprazole sodium | ||
|---|---|---|---|---|
| CAS Number | 117976-90-6 | Molecular Weight | 381.424 | |
| Density | 0.45~0.55 g/ml | Boiling Point | 603.9ºC at 760 mmHg | |
| Molecular Formula | C18H20N3NaO3S | Melting Point | 140-141ºC dec. | |
| MSDS | Chinese USA | Flash Point | 319.1ºC | |
Use of Rabeprazole sodiumRabeprazole sodium(LY307640 sodium) is an antiulcer drug in the class of proton pump inhibitors.Target: Proton PumpRabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds. |
| Name | rabeprazole sodium |
|---|---|
| Synonym | More Synonyms |
| Description | Rabeprazole sodium(LY307640 sodium) is an antiulcer drug in the class of proton pump inhibitors.Target: Proton PumpRabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds. |
|---|---|
| Related Catalog | |
| References |
| Density | 0.45~0.55 g/ml |
|---|---|
| Boiling Point | 603.9ºC at 760 mmHg |
| Melting Point | 140-141ºC dec. |
| Molecular Formula | C18H20N3NaO3S |
| Molecular Weight | 381.424 |
| Flash Point | 319.1ºC |
| Exact Mass | 381.112305 |
| PSA | 93.41000 |
| LogP | 3.48420 |
| Storage condition | Hygroscopic, -20°C Freezer, Under Inert Atmosphere |
| Water Solubility | H2O: soluble10mg/mL (clear solution) |
| RIDADR | NONH for all modes of transport |
|---|---|
| HS Code | 2933399090 |
|
~97%
Rabeprazole sodium CAS#:117976-90-6 |
| Literature: US2007/225502 A1, ; Page/Page column 5 ; |
|
~%
Rabeprazole sodium CAS#:117976-90-6 |
| Literature: WO2004/63188 A1, ; Page 13 ; |
|
~%
Rabeprazole sodium CAS#:117976-90-6 |
| Literature: WO2008/45777 A2, ; Page/Page column 32 ; |
|
~%
Rabeprazole sodium CAS#:117976-90-6 |
| Literature: WO2008/146297 A2, ; Page/Page column 6 ; |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| HS Code | 2933399090 |
|---|---|
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Development of alginate-reinforced chitosan nanoparticles utilizing W/O nanoemulsification/internal crosslinking technique for transdermal delivery of rabeprazole.
Life Sci. 110(1) , 35-43, (2014) First; to develop rabeprazole (RP)-alginate core coated chitosan nanoparticles (NP) utilizing water in oil (W/O) nanoemulsion technique. Second; formulation of transdermal patches loaded RP-NP that av... |
|
|
Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.
J. Infect. Dis. 208(7) , 1123-30, (2013) Clarithromycin-resistant Helicobacter pylori is associated with point mutations in the 23S ribosomal RNA (rRNA) gene.A total of 1232 patients participated and were divided into 2 control groups and 1 ... |
|
|
Increased gap density predicts weakness of the epithelial barrier in vivo by confocal laser endomicroscopy in indomethacin-induced enteropathy. Shi S, Wang H, Gao H, et al.
Dig. Dis. Sci. 59(7) , 1398-405, (2014)
|
| natrium-2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-id |
| Sodium 2-({[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl}sulfinyl)benzimidazol-1-ide |
| 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (1:1) |
| RABEPRAZOLE NA |
| sodium,2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide |
| sodium 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-benzimidazol-1-ide |
| Pariet |
| Zechin |
| Rabonik |
| sodium 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-ide |
| Rebeprazole sodium |
| Aciphex |
| Rabeprazole Sodium Salt |
| Rabeprazole sodium |
| 2-([4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole,Pariprazole |
| Sodium rabeprazole |
| Rabeprazole (sodium) |